BioCentury
ARTICLE | Company News

GlaxoSmithKline and Shionogi in joint venture

July 24, 2001 7:00 AM UTC

GlaxoSmithKline (GSK; LSE:GSK) and Shionogi (Osaka, Japan) will form a joint venture with operations in the U.S. and Europe to develop and market products to treat HIV infection and neurological disorders. The joint venture will have exclusive rights to four compounds from Shionogi and one from GSK. The Shionogi compounds include S-1360, an HIV integrase inhibitor in Phase II trials to treat HIV/AIDS; S-8510, a benzodiazepine partial inverse agonist in Phase II trials in Japan for Alzheimer's disease; S-0139, an endothelin-A receptor antagonist in Phase II studies in Japan to treat hemorrhagic and ischemic stroke; and S-1746, an AMPA receptor anatgonist that is expected to enter Phase I trials in the fourth quarter. GSK will contribute an endothelin-A receptor antagonist in preclinical development. ...